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Abstract
Background: The project "Antibiotic resistance in bacteria of animal origin – II" (ARBAO-II) was
funded by the European Union (FAIR5-QLK2-2002-01146) for the period 2003–2005, with the aim
to establish a continuous monitoring of antimicrobial susceptibility among veterinary laboratories
in European countries based on validated and harmonised methodologies. Available summary data
of the susceptibility testing of the bacterial pathogens from the different laboratories were
collected.
Method: Antimicrobial susceptibility data for several bovine pathogens were obtained over a three
year period (2002–2004). Each year the participating laboratories were requested to fill in excel-
file templates with national summary data on the occurrence of antimicrobial resistance from
different bacterial species.
A proficiency test (EQAS – external quality assurance system) for antimicrobial susceptibility
testing was conducted each year to test the accuracy of antimicrobial susceptibility testing in the
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participating laboratories. The data from this testing demonstrated that for the species included in
the EQAS the results are comparable between countries.
Results: Data from 25,241 isolates were collected from 13 European countries. For Staphylococcus
aureus from bovine mastitis major differences were apparent in the occurrence of resistance
between countries and between the different antimicrobial agents tested. The highest frequency of
resistance was observed for penicillin. For Mannheimia haemolytica resistance to ampicillin,
tetracycline and trimethoprim/sulphonamide were observed in France, the Netherlands and
Portugal. All isolates of Pasteurella multocida isolated in Finland and most of those from Denmark,
England (and Wales), Italy and Sweden were susceptible to the majority of the antimicrobials.
Streptococcus dysgalactiae and Streptococcus uberis isolates from Sweden were fully susceptible. For
the other countries some resistance was observed to tetracycline, gentamicin and erythromycin.
More resistance and variation of the resistance levels between countries were observed for
Escherichia coli compared to the other bacterial species investigated.
Conclusion: In general, isolates from Denmark, England (and Wales), the Netherlands, Norway,
Sweden and Switzerland showed low frequencies of resistance, whereas many isolates from
Belgium, France, Italy, Latvia and Spain were resistant to most antimicrobials tested. In the future,
data on the prevalence of resistance should be used to develop guidelines for appropriate
antimicrobial use in veterinary medicine.
Background
Antimicrobial agents are widely used for the treatment of
bovine mastitis, respiratory tract infections and diarrhoea
in cattle. During acute infections and outbreaks of infec-
tious disease in groups or herds it is important to use an
effective antimicrobial treatment as early as possible. This
empirical treatment is generally based on knowledge of
the resistance pattern of the different bacterial pathogens
to antimicrobial agents used in the particular animal spe-
cies.
Antimicrobial resistance is an increasingly important
problem among several bacterial species causing infection
in animals and humans in recent year. The problem for
some bacterial species is so critical that there is few treat-
ment options left [1,2].
The initial treatment of animals is commonly based on
the experience regarding the expected resistance of the
infectious agent. The fact that occurrence of antimicrobial
resistance varies between countries and regions has the
potential to complicate that matter. Furthermore, knowl-
edge of expected resistance is limited by the small propor-
tion of different bacterial pathogens from infected
animals that actually are investigated for their antimicro-
bial resistance pattern.
To address this the ARBAO-II-project was funded by the
European Union (FAIR5-QLK2-2002-01146) for the
period 2003–2005, The aim of this project was to estab-
lish a continuous monitoring of antimicrobial suscepti-
bility among veterinary laboratories in European
countries based on validated and harmonised methodol-
ogies. Available summary data of the susceptibility testing
of the bacterial pathogens from the different laboratories
were collected and is herewith made publicly available.
In this report the first data on the prevalence of antimicro-
bial resistance among bacterial pathogens isolated from
cattle are reported.
Methods
Participating laboratories
Each year the laboratories participating in the project were
requested to fill in excel-file templates with national sum-
mary data on the occurrence of antimicrobial resistance
from different bacterial species and groups. The partici-
pants were asked to submit national data but if this was
not possible they were advised to submit regional or insti-
tutional data as done by England (and Wales). The data
for some countries might be incomplete e.g. Latvia, Fin-
land and Portugal and data were deducted for others if the
number of isolates were lower than 9. The bacterial spe-
cies and their antimicrobial resistances are given in Table
1 and Tables 2, 3, 4, 5, 6, respectively.
Quality control
Invitation was annually announced through the network
by email or facsimile to all ARBAO members to participate
in self-evaluating proficiency tests (EQAS external quality
assurance system) for antimicrobial susceptibility testing.
The tests were conducted each year to test if the current
methodologies were accurate, adequate and reliable [3,4].
In addition, the EQAS served as a tool to point out the lab-
oratories from where annual data were reliable. The goal
was to have all laboratories to perform antimicrobial sus-Acta Veterinaria Scandinavica 2008, 50:28 http://www.actavetscand.com/content/50/1/28
Page 3 of 10
(page number not for citation purposes)
ceptibility testing with a maximum of 10% total devia-
tions (minor, major, or very major deviations) and a
maximum of 5% critical deviations (major or very major
deviations).
Eight strains of each species (Staphylococcus aureus, Man-
nheimia haemolytica, Pasteurella multocida, Streptococcus dys-
galactiae, Streptococcus uberis and  Escherichia coli) were
selected for each EQAS iteration. Strains were obtained
from the isolate collection of the National Food Institute,
Technical University of Denmark (DTU Food). All strains
were included in only one EQAS iteration. The strains
were inoculated to agar stab cultures for shipping to par-
ticipating laboratories. Participating laboratories also
received a lyophilised reference strain as a quality control
strain for susceptibility testing (E. coli ATCC 25922;
Campylobacter jejuni ATCC 33560; Enterococcus faecalis
ATCC 29212, S. aureus ATCC 25923, and S. aureus ATCC
29213) in each EQAS shipment.
Participating laboratories were instructed to follow the
enclosed testing instructions; subculture the test strains,
and propagates the quality control strains prior to per-
forming the susceptibility method that was routinely used
by their laboratory. In addition, laboratories were advised
to maintain the quality control strain for future profi-
ciency tests. After completion of the susceptibility testing
of the test strains and the quality control strain, the partic-
ipating laboratories were instructed to record the obtained
results, using MIC values or zone-diameter in millimetres,
and categorize each of the tested strains as either "resist-
ant" (R), "intermediate" (I) or "susceptible" (S) against
each tested antimicrobial agent using the breakpoints rou-
tinely used in their laboratory. They were then asked to
record the information on the participating laboratory
record sheet.
After submitting results, participating laboratories
received an individual report. The individual reports for
the participating laboratories reported all deviations from
the expected values and suggestions of how to either solve
or investigate the problem. For the quality control strains,
deviations were defined as values that exceeded the qual-
ity control range of the strain. Deviations of the antimicro-
bial susceptibility results were categorised as minor, major
or very major. A minor deviation was defined as an inter-
mediate strain that was classified as susceptible or resist-
ant or vice versa (i.e. I ↔ S or I ↔ R). A major deviation
Table 1: Data of antimicrobial susceptibility submitted from the participating laboratories in the different European countries during a 
three years period.
Bacterial species Year Country and number of bacterial species Total No. of 
isolates
BDE c FIN Fa IL V N L PNE S SC H
S. aureus 2002 - 101 688 - 23–174 - - 110 - - 147 100 - 1 170–1 321
2003 - 99 378 - 8–233 63 - 107 - 117 192 - 60 1 024–1 249
2004 - - 340 - - - 59 99 - - 112 - 81 691
M. haemolytica 2002 - - 78 - 20–56 - - - 57 - - - - 155–191
2003 - 19 90 - 4–68 9 - 35 - - - - - 157–221
2004 - - 101 - - - - 16 - - - - - 117
P. multocida '2002 - 26 113 - 21–85 - - - - - - - - 160–224
2003 - 48 154 15 10–218 24 - 45 - - - - - 296–504
2004 - - 178 - - - - 16 - - - - - 194
S. dysgalactiae 2002 - - 278 - 27–36 - - 107 - - - 100 - 512–521
2003 - - 193 - 41–51 - - 94 - - - - - 328–338
2004 - - 165 - - - - 90 - - - - - 255
S. uberis 2002 - - 1 195 - 195–291 - - 103 - - - 98 - 1 591–1 687
2003 - - 775 - 471–610 27 - 83 - - - - - 1 356–1 495
2004 - - 885 - - - - 99 - - - - - 984
E. coli (infections) 2002 102b 101 4 193 - 49–1 234 50 - 105 - - 136 - - 4 736–5 921
2003 56b 57 2 659 - 150–1 835 75 - 153 - - 155 169 16 3 490–5 175
2004 237b 79 3 576 - - 28 101 - - 87 29 16 4153
Total 2002 102 228 6 545 0 335–1 876 50 0 425 57 0 283 298 0
2003 56 223 4 249 15 684–3 015 198 0 517 0 117 347 169 76
2004 237 79 5 245 0 0 28 59 421 0 0 199 29 97
a: Multicenter study. The isolates were tested for different panels of antimicrobial agents in the different centers. b: Veal calves. c: Isolates from 
England included also Wales and have been collected by The Veterinary Laboratory Agency. The remaining part of the United Kingdom has 
separate laboratories. B – Belgium; DK – Denmark; E – England, FIN – Finland; F – France; I – Italy; LV – Latvia; NL – The Netherlands; P – Portugal; 
N – Norway; ES – Spain; S – Sweden; CH – Switzerland.Acta Veterinaria Scandinavica 2008, 50:28 http://www.actavetscand.com/content/50/1/28
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was defined as a susceptible strain that was classified as
resistant (i.e. S → R). A very major deviation was defined
as a resistant strain that was classified as susceptible (i.e. R
→ S).
The overall performance was between 85%–100% cor-
rectly categorized isolates. In general, the concordance
between the expected results and the participants' results
for Enterobacteriaceae was highest. Data from laboratories
performing unsatisfactory in the EQAS (performance
below 90% correctly categorized results) were not
included in the present report. The summary results for
the bacterial species included in the EQAS are considered
to be comparable between countries, but there is a poten-
tial bias due to differences in sampling and microbiologi-
cal methods used for isolation in the different countries.
The EQAS results for streptococci and staphylococci were
less favourable that for Enterobacterriaceae.
Testing methods
Each participating laboratory reported annually which
methods were used for antimicrobial susceptibility test-
ing. Laboratories from England (and Wales), France, Italy,
Latvia and Portugal used disc diffusion tests, whereas
Denmark, the Netherlands, Norway, Sweden and Switzer-
land used the broth micro dilution method by which the
minimal inhibition concentration (MIC) is determined.
Spain and Finland both used MIC determination as well
Table 2: Occurrence of antimicrobial resistance among Staphylococcus aureus from bovine mastitis in different European countries.
Antimicrobial agent Year Country and prevalence of resistance
DK E F I LV NL N ES S CH
C h l o r a m p h e n i c o l 2 0 0 2 0 . 0 ----- - 0 . 5 1 . 0 -
2003 0.0 - 0.0 1.0 - - 0.0 0.0 - -
2 0 0 4 ---- 2 . 1 - - 1 . 8 - -
Erythromycin 2002 1.0 3.0 11.4 - - 0.9 - 2.0 1.0 -
2003 0.0 4.0 7.0 4.0 - 0.0 1.0 4.2 - 0.0
2004 - 2.0 - - 0.0 0.0 - 1.8 - 3.7
Gentamicin 2002 0.0 - 2.2 - - - - 0.0 0.0 -
2003 0.0 - 1.0 1.0 - - 0.0 - - 30
2 0 0 4 ---- 3 . 1 - - - - 2 . 5
Oxacillin 2002 0.0 - 8.3 - - 0.0 - 0.5 0.0 -
2003 - - 1.0 0.0 - 0.0 0.0 0.0 - -
2 0 0 4 ---- 0 . 0 0 . 0 - 3 . 7 - 0 . 0
Penicillin 2002 29.7 46.0 4.7 - - 10.0 - 45.0 7.0 -
2003 23.1 36.0 3.0 43.0 - 24.3 5.0 40.1 - -
2004 - 38.0 - - 49.0 12.1 - 33.0 17.3
Streptomycin 2002 4.0 - 7.5 - - 1.8 - - 1.0 -
2003 1.0 - 8.0 8.0 - 1.9 2.0 6.3 - 5.0
2 0 0 4 ---- 0 . 0 2 . 0 - 6 . 3 - -
Sulphonamides 2002 4.0 - 59.2 - - - - 0.0 - -
2003 0.0 - 2.0 0.0 - - - - - 0.0
2 0 0 4 ------ - 0 . 0 - -
Tetracycline 2002 3.0 8.0 9.2 - - 0.0 - 3.5 0.0 -
2003 2.0 3.0 9.0 13.0 - 2.8 0.0 2.1 - -
2004 - 4.0 - - 2.1 2.0 - 5.4 - 6.2
TMP + Sulphonamides 2002 - - 1.7 - - 0.0 - - 0.0 -
2003 - - 0.0 0.0 - - - - - -
2 0 0 4 ---- 0 . 0 0 . 0 - - - -
Trimethoprim 2002 1.0 - 11.1 - - - - 4.5 - -
2003 1.0 - 0.0 - - - 0.0 3.1 - 0.0
2 0 0 4 ---- 2 . 9 - - 0 . 0 - -
Neomycin 2002 0.0 0.4 ---- - - - -
2003 - 0.0 2.0 - - - 1.0 - - 0.0
2004 - 0.3 - - 5.3 0.0 - - - -
Ceftiofur 2002 0.0 - 4.2 - - - - 0.0 - -
2003 0.0 - 1.0 - - - - 0.0 - -
2 0 0 4 ---- 0 . 0 - - 0 . 9 - -
DK – Denmark; E – England, F – France; I – Italy; LV – Latvia; NL – The Netherlands; P – Portugal; N – Norway; ES – Spain; S – Sweden; CH – 
Switzerland.Acta Veterinaria Scandinavica 2008, 50:28 http://www.actavetscand.com/content/50/1/28
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as disc diffusion, whereas Belgium used tablet diffusion.
The manufactures of discs and microtitre plates for broth
micro dilution differed between countries.
All countries have reported whether they to some extend
or in all aspects followed the standards of the Clinical and
Laboratory Standards Institute (CLSI), M31-A2, M7-A6 or
Table 3: Occurrence of antimicrobial resistance among Mannheimia haemolytica isolated from cattle in different European countries
Antimicrobial agent Year Country and prevalence of resistance
DK E F I P NL
Ampicillin 2002 - 0.0 20.4 - 13.0 -
2003 0.0 10.0 5.0 11.1 - 25.7
2004 - 2.0 - - - 6.3
Amoxicillin + Clavulanic. acid 2002 - 0.0 0.0 - 0.0 -
2003 - 3.0 0.0 0.0 - 0.0
2 0 0 4 - 0 . 0 ----
Ceftiofur 2002 - - 0.0 - - -
2003 0.0 - 0.0 - - 0.0
2004 - - - - - 0.0
Fluoroquinolones 2002 - 0.0 5.0 - 0.0 -
2003 0.0 0.0 5.0 0.0 - 5.8
2004 - 0.0 - - - 0.0
Florfenicol 2002 - 0.0 0.0 - - -
2003 0.0 1.0 2.0 0.0 - 0.0
2004 - 0.0 - - - 0.0
Tetracycline 2002 - 3.0 40.0 - 38.0 -
2003 0.0 13.0 33.0 11.1 - 51.4
2004 - 1.0 - - - 31.0
TMP + Sulphonamides 2002 - 1.0 16.6 - - -
2003 0.0 4.0 16.0 0.0 - 8.6
2004 - 0.0 - - - 0.0
DK – Denmark; E – England, F – France; I – Italy; NL – The Netherlands; P – Portugal.
Table 4: Occurrence of antimicrobial resistance among Pasteurella multocida isolated from cattle in different European countries
Antimicrobial agent Year Country and prevalence of resistance
DK E FIN F I NL
Ampicillin 2002 0.0 1.0 - 5.3 - -
2003 6.25 0.6 0.0 2.0 0.0 2.2
2004 - 1.0 - - - 0.0
Amoxicillin + Clavulanic acid 2002 - 2.0 - 0.0 - -
2003 - 0.0 - 0.0 0.0 -
2004 - 0.0 - - - -
Ceftiofur 2002 0.0 - - 1.2 - -
2003 0.0 - - 0.0 - 0.0
2004 - - - - - 0.0
Fluoroquinolones 2002 0.0 0.0 - 4.7 - -
2003 0.0 0.0 0.0 0.0 0.0 0.0
2004 - 0.0 - - - 6.3
Florfenicol 2002 0.0 2.0 - 0.0 - -
2003 0.0 0.6 - 0.0 0.0 0.0
2004 - 0.0 - - - 0.0
Tetracycline 2002 12.0 6.0 - 10.7 - -
2003 0.0 4.0 0.0 12.0 24.0 20.0.
2004 - 1.0 - - - 12.5
TMP + Sulphonamides 2002 8.0 3.0 - 7.0 - -
2003 0.0 1.0 0.0 3.0 4.0 2.2
2004 - <1.0 - - - 0.0
DK – Denmark; E – England, FIN – Finland; F – France; I – Italy; NL – The Netherlands.Acta Veterinaria Scandinavica 2008, 50:28 http://www.actavetscand.com/content/50/1/28
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M2-A8 [5] to determine zone sizes and MIC values. Eng-
land (and Wales), France, the Netherlands, Norway, Swe-
den and Switzerland reported that they did not
completely use CLSI breakpoints as their means of deter-
mining the antimicrobial susceptibility levels (referring to
the CLSI breakpoints listed in the fifteenth international
supplement M100-S15). The antimicrobials tested against
S. aureus, M. haemolytica, P. multocida, S. dysgalactiae, S.
uberis and E. coli are given in Tables 2, 3, 4, 5, 6.
Results
Susceptibility data were obtained from 25,241 bacterial
isolates isolated in 13 European countries over a three
year period, 2002–2004 (Table 1). Not all countries were
equal participants in that some countries submitted data
on a single bacterial species, e.g. Belgium, Finland, Latvia,
Portugal and Norway, whereas other countries provided
data for multiple bacterial species.
Staphylococcus aureus
Susceptibility data for S. aureus from bovine mastitis were
obtained from ten of the 13 participating countries. In
total between 691–1,321 isolates were tested depending
on the year and number of countries submitting date for
that year (Table 1). In general, a relatively low frequency
of resistance was observed in all countries over the years
(Table 2). However, a higher level, e.g., > 10%, resistance
was noted to penicillin in almost all countries with the
exception of France, Norway and Sweden.
Mannheimia haemolytica
Susceptibility data for M. haemolytica from infections in
cattle were obtained from a total of six countries (Table 3).
The six countries tested between 117–221 isolates. In gen-
eral, the level of resistance was relatively low with the
exception of tetracycline and ampicillin in all countries
over the years (Table 3). Resistance to ceftiofur was not
detected among the 529 isolates tested.
Pasteurella multocida
Susceptibility data for P. multocida from infections in cat-
tle were obtained from a total of six countries. Results
from a total of 194–504 tested isolates were submitted
(Table 1). In general, a relatively low frequency of resist-
ance was observed in all countries over the years (Table 4).
Table 5: Occurrence of antimicrobial resistance among Streptococcus spp. from cases of bovine mastitis in different countries in 
Europe.
Antimicrobial agent Year Bacterial species, country and prevalence of resistance
S. uberis S. dysgalactiae
EFI N L S EF N L S
Chloramphenicol 2002 - - - - 0.0 - - - 0.0
2003 - - 7.0 - - - - - -
2004 - - - - - - - - -
Erythromycin 2002 8.0 22.2 - 21.4 0.0 3.0 14.8 14.0 0.0
2003 8.0 17.0 22.0 19.3 - 5.0 17.0 12.8 -
2004 8.0 - - 0.0 - 2.0 - 6.7 -
Gentamicin 2002 - 52.7 - - - - 11.7 - -
2003 - - 52.0 - - - - - -
2004 - - - - - - - - -
Penicillin 2002 0.3 0.4 - 3.9 0.0 0.7 3.4 0.0 0.0
2003 0.0 1.0 0.0 0.0 - 0.0 0.0 0.0 -
2004 0.0 - - 0.0 - 0.0 - 0.0 -
Tetracycline 2002 15.0 20.9 - 33.0 2.0 46.0 41.6 76.6 6.0
2003 11.0 17.0 44.0 41.0 - 47.0 53.0 76.6 -
2004 15.0 - - 35.4 - 39.0 - 67.8 -
TMP + Sulphonamides 2002 - 0.8 - 8.7 0.0 - 6.6 0.0 0.0
2003 - 0.0 - 1.2 - - 4.0 0.0 -
2004 - - - 0.0 - - - 0.0 -
E – England, F – France; I – Italy; NL – The Netherlands; S – Sweden.Acta Veterinaria Scandinavica 2008, 50:28 http://www.actavetscand.com/content/50/1/28
Page 7 of 10
(page number not for citation purposes)
Streptococcus uberis
Susceptibility data for S. uberis from mastitis in cattle were
obtained from five countries (Table 1). The number of
isolates tested was 984–1,687. In general, a relatively
moderate frequency of resistance was observed in all
countries over the years (Table 5). Major differences were
observed between countries and some variation also over
years.
Table 6: Occurrence of antimicrobial resistance among Escherichia coli isolated from cattle suffering from either diarrhoea or mastitis 
in different European countries.
Antimicrobial agent Year Country and prevalence of resistance
B DK E F I LV ES NL S CH
Origin Diarrhoea Mastitis
Ampicillin 2002 63.7 79.0 44.0 76.1 44.0 - 45.6 13.3 - -
2003 64.0 75.4 49.0 76.0 41.0 67.0 45.5 18.8 7.0 33.5
2004 75.5 72.1 53.0 - 25.0 - 51.0 13.9 29.0 0.0
Amoxicillin + Clavulanic acid 2002 47.0 - 14.0 30.0 14.0 - 10.3 1.0 - -
2003 16.0 3.5 19.0 34.0 6.0 54.0 4.5 1.0 - 0.0
2004 10.1 1.2 19.0 - 7.4 - 9.0 0.0 - 0.0
Apramycin 2002 10.8 0.0 3.0 17.2 - - 3.7 - - -
2003 10.0 3.6 3.0 11.0 - - 5.2 - 0.0 -
2004 8.0 0.0 3.0 - - - 6.0 - - -
Ceftiofur 2002 0.0 0.0 - 1.2 - - 5.9a 0.0 - -
2003 2.0 0.0 - 0,7 - 0.0 2.6a 0.0 0.0 0.0
2004 6.3 0.0 - - 7.1 - 6.0a 0.0 0.0 -
Chloramphenicol 2002 54.9 13.0 - 65.4 30.0 - 29.4 - - -
2003 48.0 14.1 - 58.0 21.0 - 33.8 - 2.0 18.0
2004 52.7 22.8 - - - - 31.0 - 5.0 13.3
Fluoroquinolones 2002 35.3 1.0 0.1 31.2 22.0 - 11.8 0.0 - -
2003 26.0 1.8 0.04 20.0 15.0 0.0 12.3 0.0 1.0 6.0
2004 32.1 7.6 0.0 - 11.5 - 20.0 1.0 10.0 0.0
Florfenicol 2002 31.4 1.0 - 12.6 - - 8.1 - - -
2003 26.0 3.5 - 12.0 - - 9.7 - 0.0 -
2004 21.5 5.1 - - - - 8.0 - 0.0 -
Gentamicin 2002 53.3 1.0 - 21.6 12.0 - 14.0 0.0 - -
2003 16.0 3.6 - 20.0 1.0 29.0 19.5 0.0 0.0 6.0
2004 7.6 7.6 - - 7.1 - 25.0 0.0 0.0 6.7
Nalidixic acid 2002 42.2 19.0 - 35.0 30.0 - 21.3 1.0 - -
2003 38.0 14.1 - 36.0 21.0 56.0 18.8 - 3.0 -
2004 54.0 29.1 - - 21.4 - 31.0 - 14.0 -
Neomycin 2002 46.0 9.0 26.0 42.5 - - 25.0 7.6 - -
2003 26.0 15.8 27.0 44.0 - 86.0 25.0 6.9 1.0 18.0
2004 17.7 45.6 30.0 - - - 26.0 5.0 7.0 -
Streptomycin 2002 - 70.0 - 78.6 24.0 - 52.2 15.2 - -
2003 - 68.4 - 78.0 54.0 69.0 54.8 20.8 11.0 -
2004 - 87.3 - - 25.0 - 55.0 15.8 48.0 -
Sulphonamides 2002 - 74.0 - 80.6 46.0 - 45.6 - - -
2003 - 65.0 - 69.0 47.0 100.0 52.9 - 8.0 -
2004 - 94.9 - - 25.0 - 51.0 - 41.0 -
Tetracycline 2002 58.8 84.0 48.0 79.5 56.0 - 49.3 14.3 - -
2003 64.0 75.5 52.0 76.0 52.0 71.0 56.5 20.8 5.0 24.0
2004 76.4 84.8 57.0 - 28.6 - 59.0 14.9 37.0 20.0
Trimethoprim 2002 - 54.0 - 52.4 - - 33,1 - - -
2003 - 52.6 - 39.0 - 0.0 41.9 - 3.0 -
2004 - 70.9 - - - - 41.0 - 10.0 -
TMP + Sulphonamide 2002 56.9 - 23.0 39.5 26.0 - - 11.4 - -
2003 44.0 - 27.0 35.0 24.0 0.0 - 10.9 - 12.5
2004 54.0 - 28.0 - 8.7 - - 8.9 - -
a: Cefotaxime
B – Belgium; DK – Denmark; E – England; F – France; I – Italy; LV – Latvia; NL – The Netherlands; ES – Spain; S – Sweden; CH – Switzerland.Acta Veterinaria Scandinavica 2008, 50:28 http://www.actavetscand.com/content/50/1/28
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Streptococcus dysgalactiae
Susceptibility data for 255–521 S. dysgalactiae isolates
from mastitis in cattle were obtained from the same coun-
tries as for S. uberis (Table 1). In general, there was an
increased frequency of resistance observed in all countries
over the years. Most noticeable was a very high level of
resistance against tetracycline (Table 5). Major differences
were observed between countries and some variation also
over years.
Escherichia coli
Susceptibility data for E. coli from diarrhoea in calves and
mastitis in cattle and surveillance programmes were
obtained from ten countries (Table 6), which submitted
susceptibility data for 3 490–5,921 isolates. A high preva-
lence of resistance was observed in this pathogen com-
pared to the other species investigated (Table 6). Major
variations between countries and antimicrobial agents
were apparent.
Discussion
The data presented in this report originate from samples
submitted to diagnostic laboratories in different coun-
tries. It was generally impossible to retrieve data on the
specific age of the animals and additionally, the specific
microbiological methods used to isolate and identify the
organisms remained unreported. All participating labora-
tories are, however, appointed national reference labora-
tories for antimicrobial resistance.
Information on antimicrobial usage prior to collection of
the samples could have indicated why resistance in some
countries is higher than in others, and also, it could have
indicated a reason for the difference seen between antimi-
crobials. As information on these key determinants is not
available, comparisons and conclusions have to be done
with care. Nevertheless, the study provides interesting
data on the prevalence of antimicrobial resistance in bac-
terial pathogens in different European countries.
Although there was a prior agreement between the partic-
ipating laboratories on a list of antimicrobials of relevance
for each bacterial species, most laboratories provided data
for different panels of antimicrobial agents. The same het-
erogeneity was observed in the breakpoints applied. This
demonstrates an important problem in performing inter-
national monitoring based on data produced by routine
diagnostic laboratories using different panels, methods,
equipment etc. [6,7]. We are aware that publishing data
from multiple laboratories can be very problematic as
there might be variations in methods used, interpretative
criteria, etc. In the ideal world all laboratories would use
the same methods and we could believe that data were
directly comparable. However, since this unfortunately
not is the case and there actually are major differences in
the methods used we decided to ensure the comparability
of the data as means of gaining reliable by conducting an
external quality control system and only include data
from laboratories and pathogens where the cut-off was
met.
Staphylococcus aureus
In a previous survey of isolates from nine European coun-
tries and USA, major variations in the occurrence of resist-
ance between countries were reported [8]. This
emphasises that treatment strategies for bovine mastitis
caused by S. aureus in the European countries have to be
based on local knowledge and available resistance data. In
the present study, it seems that the level of resistance in
France has decreased between the years 2002 and 2003;
for oxacillin (8.3% to 1%), for sulphonamide (59.2% to
2%) and for trimethoprim (11.1% to 0%). It was not pos-
sible to detect the same trend in the year 2004 due to the
absence of submitted data. Similar trends were only
observed in one other country (Switzerland), where a con-
siderable decrease of gentamicin resistance from 30% to
2.5% was observed.
Of major concern is the level of resistance to oxacillin and
3rd generation cephalosporins (i.e. ceftiofur) in S. aureus.
The prevalence of oxacillin resistance in Spain (3.7%) and
France (8.3%) and the resistance towards cephalosporins
in Spain (0.9% in 2004) and France (4.2% in 2002; 1% in
2003) indicate the presence of methicillin resistant S.
aureus (MRSA) in these two countries. Most of the Spanish
isolates were not multi resistant which usually a feature of
MRSA isolated from humans is. Furthermore, the pres-
ence of the mecA-gene could not be confirmed since the
strains were not stored.
For France the percentages of resistance observed by oxa-
cillin resistant S. aureus isolates must be interpreted with
a great deal of precaution. Data on bovine pathogens were
collected through a multi centre study (see Table 1). The
results could not be verified because some of the labora-
tories involved in the network did not store the strains.
From 2003, all the strains collected in France were inves-
tigated specifically for methicillin resistance and a
decrease was observed. MRSA are not commonly seen in
bovine mastitis but this has recently been reported in
Korea [9] and Hungary [10]. MRSA also seems to be
emerging within other livestock species [11,12].
Mannheimia haemolytica
The decrease in resistance levels to antimicrobials in iso-
lates from the Netherlands to ampicillin, fluoroqui-
nolone, tetracycline, trimethoprim – sulphonamide may
partly be explained by sampling bias (sampling of differ-
ent age groups between years). The same tendency was
observed in both England (and Wales) and France toActa Veterinaria Scandinavica 2008, 50:28 http://www.actavetscand.com/content/50/1/28
Page 9 of 10
(page number not for citation purposes)
some of the antimicrobials. In France the level of resist-
ance to ampicillin and tetracycline decreased from 2002
to 2003 whereas a decrease in England (and Wales) was
observed for ampicillin, amoxicillin – clavulanic acid, tet-
racycline and trimethoprim – sulphonamide in the period
2003 to 2004. Resistance to fluoroquinolones was
detected in France with 5% (2002) and in the Netherlands
(enrofloxacin) with 5.8% (2003). Similar results have pre-
viously been reported from France [13] and the Nether-
lands [14], whereas a similar or more frequent occurrence
of resistance has been observed in USA [15,16].
Pasteurella multocida
Antimicrobial resistance in P. multocida seems to be higher
in the Netherlands compared to the other countries (e.g.
20% to tetracycline in 2002) though the amount of resist-
ance shows a tendency to decrease over the years for amp-
icillin, tetracycline and trimethoprim – sulphonamide
(Table 4). The same trend was observed in England (and
Wales), France and Denmark to tetracycline and trimeth-
oprim – sulphonamide. It should be noted, that in 2002
in France 1.2% of the isolates were resistant to ceftiofur
and 4.7% to fluoroquinolones. Resistance to enrofloxacin
in the Netherlands was 6.3% in 2004.
Streptococcus uberis
Resistance to trimethoprim – sulphonamide and penicil-
lin seems to be low compared to the levels of resistance for
other antimicrobials tested. The percentages of resistance
to trimethoprim + sulphonamide (8.7%) and penicillin
(3.9%) were the highest values observed in the Nether-
lands. A relatively high level of resistance could be
detected in countries, which submitted data for tetracy-
cline and erythromycin as well as gentamicin (Table 5).
Similar data have been reported from USA [17,18] and
France [19]. Thus, bovine mastitis caused by streptococci
can be treated with penicillins, whereas the use of mac-
rolides and tetracyclines probably should be avoided on
the basis of the resistance data generated by this study.
Streptococcus dysgalactiae
Resistance to tetracycline and erythromycin was high
compared to the other antimicrobials tested. In the Neth-
erlands 67.8% of the isolates were resistant to tetracycline
in 2004 and 17% of the isolates from France were resistant
to erythromycin in 2003. The isolates from Sweden were
susceptible to all antimicrobials tested, except for tetracy-
cline, where the level was 6% (Table 5).
Escherichia coli
The percentage of resistant isolates increased in some
countries, whereas it decreased in others. For instance in
France and Italy the resistance levels show a tendency to
decrease for most of antimicrobials investigated between
the years 2002–2004. In Spain and Denmark the levels
seem to increase between the years 2003 and 2004. In
general, a relatively high frequency of resistance was
observed in almost all countries over the years, with the
exception of Sweden and the Netherlands the frequency
was more moderate. Resistance to ceftiofur, representing
the 3rd generation cephalosporins, was observed in France
(2002, 1.2%; 2003, 0.7%), Spain (2002, 5.9%; 2003,
2.6%; 2004, 6%), Italy (2004, 7.1%) and arising in Bel-
gium (2003, 2%; 2004, 6.3%). The frequent occurrence of
resistance to more conventional antimicrobials in most of
these countries makes cephalosporins a group of drugs
that can be used without prior susceptibility testing.
Greater than 10% fluoroquinolone resistance was
observed in Sweden (enrofloxacin), France, Spain, Bel-
gium, Germany and Italy. Higher rates of resistance
towards newer antimicrobials (e.g. fluoroquinolones,
aminoglycosides) may be due to the attitudes and practice
among European countries in prescribing and administer-
ing drugs for therapy of enteric and respiratory tract dis-
eases [20].
The seemingly emerging occurrence of resistance to the
important antimicrobial agents; cephalosporins and fluo-
roquinolones in Belgium, France, Italy and Spain is wor-
rying. These four countries had in general the highest
frequency of resistance to most antimicrobial agents,
potentially making treatment difficult.
Conclusion
A frequent occurrence of resistance to several antimicro-
bial agents was observed and major differences between
countries are apparent. This may reflect differences in the
antimicrobial use between countries and veterinarians.
This study supports the premise that the treatment of
infected animals has to be based on local knowledge and
the observed resistance patterns.
Some limitations in the study design were apparent.
Because of this precautions should be taken when com-
paring the summary data. Furthermore, differences in
antimicrobial resistance testing and to some extend differ-
ences in breakpoint used may also complicate the com-
parison between the countries. The use of an external
quality assurance system did, however, reveal that the
influence of the differences and lack of standardisation
might be minor.
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